《瑞銀窩輪》ATM整體向下 看好可留意阿里認購(16593)
ATM 整體向下,其中阿里(09988)跌幅較深,周四低開於其20天線水平後跌幅一再擴大,最終下跌2.55%,收報82.2港元。騰訊(00700)、美團(03690)則分別下跌0.8%及1.9%。由於ATM股價下跌,資金流方面亦吸引不少投資者部署ATM的相關好倉產品趁低吸納。如投資者看好阿里,可留意阿里認購(16593),行使價90.05港元,23年9月到期,有效槓桿約7.6倍。如投資者看好騰訊,可留意騰訊認購(16759),行使價400.2港元,23年9月到期,有效槓桿約10倍。如投資者看好美團,可留意美團認購(17355),行使價155.1港元,23年10月到期,有效槓桿約7.2倍。相反,如投資者看淡阿里,可留意阿里熊證(67439),收回價93港元,行使價94.5港元,24年4月到期,有效槓桿約7.4倍。如投資者看淡騰訊,可留意騰訊認沽(15493),行使價288.68港元,23年12月到期,有效槓桿約6.1倍。如投資者看淡美團,可留意美團認沽(17833),行使價107.9港元,23年12月到期,有效槓桿約4倍。
港交所(0388)近日一直徘徊約300港元的重要心理關口,最新微跌0.6%,收報299港元。對於較早前推出的雙櫃台模式,港交所的管理層表示市場反應正面,不過認為在其流動性和規模增長方面則需要較長時間。其實港交所自六月十九日開始股價走弱,半個月以來港交所股價大約下跌5.7%。直至六月二十八日,港交所再宣佈計劃推行IPO結算平台FINI:將新股定價以及股份開始交易之間的時間由五個營業日縮減至兩個營業日。如投資者看好港交所走勢可以因而受帶動,如投資者看好港交所,可留意港交認購(17043),行使價360.2港元,23年12月到期,有效槓桿約9.7倍。如投資者看淡港交所,可留意港交認沽(15553),行使價269.8港元,23年9月到期,有效槓桿約11.倍。
周四醫藥股走弱,其中藥明(002269)自六月二十日股價暴跌17%後,股價一直未能有大反彈,最新藥明下跌4.9%,收報35.95港元,重回去年十月底時的水平。未知藥明後市走勢會繼續「沉底」抑或是「尋底」。不過根據瑞銀周四即市資金流,較多投資者趁藥明股價下跌而買入相關好倉產品搏其股價反彈,如投資者看好藥明,可留意藥明認購(27772),行使價46.05港元,23年12月到期,有效槓桿約4.5倍。如投資者看淡藥明,可留意藥明熊證(67483),收回價45港元,行使價46.5港元,24年5月到期,有效槓桿約3.7倍。
更多窩輪牛熊資訊:瑞銀認股證牛熊證網站: http://www.ubs.com/hkwarrants
輪證教學及巿況焦點短片:
https://www.youtube.com/channel/UCKw86qy4eBAInmd52MND45Q?view_as=subscriber
瑞銀認股證牛熊證團隊
本產品並無抵押品。 如發行人無力償債或違約,投資者可能無法收回部份或全部應收款項。筆者為UBS AG的代表(作為證監會持牌人),並未持有相關上市公司的任何財務權益。本資料由瑞銀刊發,其並不構成買賣建議、邀請、要約或遊說。結構性產品價格可急升或急跌,投資者可能會蒙受全盤損失。過往表現並不反映將來表現。牛熊證備強制贖回機制而可能被提早終止,屆時 (i) N類牛熊證投資者將不獲發任何金額;而(ii) R類牛熊證之剩餘價值可能為零。投資前應瞭解有關風險,並諮詢專業顧問及查閱有關上市檔。UBS Securities Hong Kong Limited為結構性產品之流通量提供者,亦可能是唯一報價者或巿場參與者。(C) UBS 2023。版權所有。~
重要聲明:
以上資訊由第三方提供,AASTOCKS.com Limited對於任何包含於、經由、連結、下載或從任何與本網站有關服務所獲得之資訊、內容或廣告,不聲明或保證其內容之正確性或可靠性。對於您透過本網站上之廣告、資訊或要約而展示、購買或取得之任何產品、資訊資料,本公司亦不負品質保證之責任。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.